Haisco Pharmaceutical Hits Day Low at CNY 71.27 Amid Price Pressure

Haisco Pharmaceutical Group Co., Ltd. experienced a significant decline today, with the stock dropping by 10.0% and reaching an intraday low of CNY 71.27. This performance contrasts sharply with the broader market, as the China Shanghai Composite index fell by only 3.05% during the same period. Despite today's downturn, Haisco has shown resilience over the longer term. Over the past month, the stock has surged by 49.1%, and it boasts a remarkable 222.2% increase over the last three years. The company's market capitalization stands at CNY 24,889 million, classifying it as a large-cap entity within the Pharmaceuticals & Biotechnology sector. Financial metrics indicate a strong operational performance, with a return on equity (ROE) of 15.84% and a notable operating cash flow of CNY 1,126.55 million. The company has also benefited from a significant reduction in raw material costs, which fell by 19.75% year-over-year. Haisco's dividend yield is currently at 1.2%, reflecting its commitment to returning value to shareholders.